Amarin | AMRN - Ordinary Share Capital


Amarin reported $20.81M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amarin USD 20.81M 13K Dec/2025
AstraZeneca USD 1.55B 73K Mar/2026
BioCryst Pharmaceuticals USD 213.06M 2.54M Dec/2025
DBV Technologies USD 235.6M 98.78M Dec/2025
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Halozyme Therapeutics USD 118.52M 741K Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 165.9M 3.93M Mar/2026
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Novartis USD 1.91B 60K Mar/2026